Suppr超能文献

38型脊髓小脑共济失调

Spinocerebellar Ataxia Type 38

作者信息

Brusco Alfredo, Di Gregorio Eleonora, Borroni Barbara

机构信息

Associate Professor in Medical Genetics, Department of Medical Sciences, University of Turin, Turin, Italy

Biologist, Città della Salute e della Scienza University Hospital, Turin, Italy

Abstract

CLINICAL CHARACTERISTICS

Spinocerebellar ataxia type 38 (SCA38) is characterized as a pure cerebellar ataxia with symptoms typically manifesting in the fourth decade of life. The most common presenting features are nystagmus and slowly progressive gait ataxia. As the disease progresses, cerebellar symptoms (limb ataxia, dysarthria, dysphagia, diplopia on the horizontal line) may emerge, and affected individuals may experience sensory loss. In the later stages of the condition, ophthalmoparesis followed by ophthalmoplegia may occur. Features that distinguish SCA38 from other spinocerebellar ataxias include without paresis, hyposmia, hearing loss, and anxiety disorder. Dementia and extrapyramidal signs are not common features of SCA38. Brain imaging typically demonstrates cerebellar atrophy mainly affecting the vermis without atrophy of the cerebral cortex and a normal appearance of the brain stem. With disease progression, nerve conduction velocities and electromyography demonstrate a sensory and motor axonal polyneuropathy in all four extremities. Life span is apparently not decreased.

DIAGNOSIS/TESTING: The diagnosis of SCA38 is established in a proband with progressive gait ataxia and a heterozygous pathogenic variant in identified by molecular genetic testing.

MANAGEMENT

Management remains supportive and may include physical therapy to ameliorate coordination difficulties; crutches and walkers; home adaptations to avoid falls or accommodate motorized chairs; speech-language therapy; weighted utensils; hearing aids for those with hearing loss; and standard therapy for anxiety. Weight control, as obesity can exacerbate difficulties with ambulation and mobility; vitamin supplements for those with reduced caloric intake. Annual examination by a physician who is experienced in movement disorders and ataxia. Alcohol and medications known to affect cerebellar function. Docosahexaenoic acid (DHA) supplementation (600 mg/day) may improve clinical symptoms and cerebellar hypometabolism; no data on the effectiveness of DHA in postponing signs and symptoms of SCA38 in asymptomatic individuals with a heterozygous pathogenic variant in have been published.

GENETIC COUNSELING

Spinocerebellar ataxia type 38 (SCA38) is inherited in an autosomal dominant manner. All reported individuals diagnosed with SCA38 have an affected parent. The offspring of an affected individual are at 50% risk of inheriting the pathogenic variant. Prenatal testing for pregnancies at increased risk is possible if the pathogenic variant in the family is known; however, requests for prenatal diagnosis of adult-onset diseases are uncommon and require careful genetic counseling.

摘要

临床特征

38型脊髓小脑共济失调(SCA38)的特征为单纯性小脑共济失调,症状通常在生命的第四个十年出现。最常见的表现特征是眼球震颤和缓慢进展的步态共济失调。随着疾病进展,可能会出现小脑症状(肢体共济失调、构音障碍、吞咽困难、水平性复视),患者可能会出现感觉丧失。在疾病后期,可能会出现眼肌轻瘫继而发展为眼肌麻痹。SCA38与其他脊髓小脑共济失调的区别特征包括无轻瘫、嗅觉减退、听力丧失和焦虑症。痴呆和锥体外系体征不是SCA38的常见特征。脑部影像学检查通常显示小脑萎缩,主要影响小脑蚓部,大脑皮质无萎缩,脑干外观正常。随着疾病进展,神经传导速度和肌电图显示四肢均存在感觉和运动轴索性多神经病。寿命显然未缩短。

诊断/检测:SCA38的诊断基于先证者出现进行性步态共济失调,且通过分子遗传学检测鉴定出杂合致病性变异。

管理

管理仍以支持性为主,可能包括物理治疗以改善协调困难;使用拐杖和助行器;对家庭环境进行改造以避免跌倒或容纳电动轮椅;言语治疗;加重餐具;为听力丧失者提供助听器;以及针对焦虑症的标准治疗。控制体重,因为肥胖会加重行走和活动困难;为热量摄入减少的患者补充维生素。由运动障碍和共济失调方面经验丰富的医生进行年度检查。避免饮酒和使用已知会影响小脑功能的药物。补充二十二碳六烯酸(DHA)(600毫克/天)可能改善临床症状和小脑代谢减低;尚无关于DHA对携带杂合致病性变异的无症状个体延缓SCA38体征和症状有效性的数据发表。

遗传咨询

38型脊髓小脑共济失调(SCA38)以常染色体显性方式遗传。所有报告的被诊断为SCA38的个体均有一位患病父母。患病个体的后代有50%的风险继承致病性变异。如果家族中的致病性变异已知,对于风险增加的妊娠可进行产前检测;然而,对成人发病疾病进行产前诊断的需求并不常见,且需要仔细的遗传咨询。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验